Current disease status-In remission Posts on Medivizor
Navigation Menu

Current disease status-In remission Posts on Medivizor

Evaluating the risk of cardiovascular disease mortality among long-term survivors of classical Hodgkin lymphoma.

Evaluating the risk of cardiovascular disease mortality among long-term survivors of classical Hodgkin lymphoma.

Posted by on Feb 28, 2023 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the risk of cardiovascular disease mortality among long-term survivors of classical Hodgkin lymphoma (cHL). The data showed that patients with early-stage HL are at a higher risk of mortality from cardiovascular disease than from cancer. Some background cHL is a cancer that starts in white blood cells called...

Read More

Is long-term treatment-free remission possible after frontline nilotinib treatment in patients with chronic phase chronic myeloid leukemia?

Is long-term treatment-free remission possible after frontline nilotinib treatment in patients with chronic phase chronic myeloid leukemia?

Posted by on Apr 21, 2021 in Leukemia | 0 comments

In a nutshell This study provided an updated 5-year assessment of treatment-free remission (TFR) after frontline nilotinib (Tasigna) treatment in patients with chronic-phase (CP) chronic myeloid leukemia (CML). The data showed sustained, long-term high TFR rates with effectiveness and safety in these patients. Some background Long-term treatments...

Read More

Non-drug therapies for the management of menopausal symptoms in breast cancer survivors.

Non-drug therapies for the management of menopausal symptoms in breast cancer survivors.

Posted by on Oct 24, 2020 in Breast cancer | 0 comments

In a nutshell This article looked at different types of non-drug therapies for the management of menopausal symptoms (MS) such as night sweats and hot flushes in breast cancer (BC) survivors. The authors concluded that cognitive-behavioral therapy (CBT) and hypnosis may offer some benefit for these women. Some background BC is the most common cancer...

Read More

Can biological therapies nivolumab and ipilimumab prevent stage IV melanoma from returning?

Can biological therapies nivolumab and ipilimumab prevent stage IV melanoma from returning?

Posted by on Jun 6, 2020 in Melanoma | 0 comments

In a nutshell This study examined if biological therapies nivolumab (Opdivo) and ipilimumab (Yervoy) could safely prevent cancer return in patients with stage IV melanoma that has been surgically removed. The results showed that nivolumab and ipilimumab were effective at preventing recurrence but nivolumab alone was safer for patients. Some...

Read More

The effects of continued blinatumomab therapy in adult patients with relapsed/refractory acute lymphoblastic leukemia

Posted by on May 3, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated treatment outcomes in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) who continued blinatumomab (Blincyto; BL) after initial therapy. The authors found that long-term BL therapy can improve survival in these patients. Some background 45% of adults with ALL experience R/R...

Read More

Surviving cancer – is there a greater risk of cardiovascular disease long-term?

Posted by on Sep 16, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors.  They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...

Read More

Surviving cancer – is there a greater risk of cardiovascular disease long-term?

Posted by on Sep 16, 2019 in Leukemia | 0 comments

In a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors.  They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...

Read More

Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy

Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy

Posted by on Aug 21, 2019 in Prostate cancer | 0 comments

In a nutshell This study aimed to evaluate the use of testosterone replacement therapy (TRT) in men who had definitive treatment for prostate cancer. The authors concluded that TRT was not associated with a higher risk of recurrence in these patients. Some background Prostate cancer (PCa) is commonly fueled by the sex hormone testosterone....

Read More